AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics is a clinical-stage biopharmaceutical company building a pipeline of small-molecule drugs from its proprietary boron chemistry platform. The company targets infectious diseases, hematologic disorders, and oncology, with candidates in development for nontuberculous mycobacterial infections, polycythemia vera, Chagas disease, and melioidosis. Its lead program, epetraborole, has advanced to Phase 3 development for treatment-refractory MAC lung disease, with multiple additional Phase 2 studies active. The boron-based chemistry approach represents a distinct structural class designed to address resistance patterns and treatment limitations in areas where existing therapies fall short.

The company’s pipeline spans both rare and serious conditions underserved by current therapeutics. Beyond the infectious disease focus, AN2 maintains advanced research programs in oncology and bone disorders, positioning itself to explore applications of its platform across multiple therapeutic areas. Recent financing activity and active clinical progression underscore the company’s commitment to advancing its candidates through development, though success in biotech remains dependent on the outcomes of clinical trials and regulatory approval pathways.